Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer

被引:47
作者
Kim, ST [1 ]
Kang, WK [1 ]
Kang, JH [1 ]
Park, KW [1 ]
Lee, J [1 ]
Lee, SH [1 ]
Park, JO [1 ]
Kim, K [1 ]
Kim, WS [1 ]
Jung, CW [1 ]
Park, YS [1 ]
Im, YH [1 ]
机构
[1] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Dept Med, Div Hematol & Oncol, Seoul 135710, South Korea
关键词
gastric carcinoma; irinotecan; 5-FU; salvage chemotherapy;
D O I
10.1038/sj.bjc.6602575
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We performed a phase II study of combination chemotherapy with irinotecan, 5-fluorouracil (5-FU) and leucovorin in metastatic gastric cancer patients who were previously treated with taxane and cisplatin, to evaluate the antitumour activity and toxicity of the combination chemotherapy. The metastatic gastric adenocarcinoma patients who were previously treated with taxane and cisplatin combination as first line, and had at least one measurable lesion, 0-2 ECOG performance status and adequate organ functions, were considered eligible. They received irinotecan (150 mg m(-2), day 1) and leucovorin (100 mg m(-2), day 1), followed by continuous infusion of 5-FU (1000 mg m(-2) day 1, days 1 and 2) every 2 weeks. Treatment was continued until progression of disease was observed. In all, 64 patients were treated with this combination chemotherapy. The median age of the patients was 55 years ( range, 33-74 years), and the median ECOG performance status was 1 (0-1, 61 (95%)). Out of 64 patients, 57 were assessable for response. Among 57 assessable patients, no complete response and 12 partial responses were observed (overall response rate, 21%; 95% confidence interval (CI), 10-32%). Stable disease was observed in 14 patients (25%) and progressive disease in 31 patients (54%). The median time to progression was 2.5 months (95% CI, 1.6-3.4) and the median overall survival since the start of the second-line modified FOLFIRI was 7.6 months (95% CI, 6.5-8.7). Grade 3-4 haematologic toxicities included neutropenia in seven patients (11%) and thrombocytopenia in five patients (8%). Grade 3-4 nonhaematologic toxicities included diarrhoea in two patients (3%) and vomiting in two patients ( 3%). There were no treatment-related deaths. The combination of irinotecan, 5-FU and leucovorin showed moderate activity and favourable toxicity profile as a second-line treatment in metastatic gastric cancer patients, who were previously treated with taxane and cisplatin.
引用
收藏
页码:1850 / 1854
页数:5
相关论文
共 24 条
[1]   CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma - Results of a Phase II study [J].
Ajani, JA ;
Baker, J ;
Pisters, PWT ;
Ho, L ;
Mansfield, PF ;
Feig, BW ;
Charnsangavej, C .
CANCER, 2002, 94 (03) :641-646
[2]  
AJANI JA, 2003, P AN M AM SOC CLIN, V22, P249
[3]   Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma [J].
Assersohn, L ;
Brown, G ;
Cunningham, D ;
Ward, C ;
Oates, J ;
Waters, JS ;
Hill, ME ;
Norman, AR .
ANNALS OF ONCOLOGY, 2004, 15 (01) :64-69
[4]  
Bae Jong Myon, 2002, Cancer Res Treat, V34, P77, DOI 10.4143/crt.2002.34.2.77
[5]   A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma [J].
Blanke, CD ;
Haller, DG ;
Benson, AB ;
Rothenberg, ML ;
Berlin, J ;
Mori, M ;
Hsieh, YC ;
Miller, LL .
ANNALS OF ONCOLOGY, 2001, 12 (11) :1575-1580
[6]   CPT-11 in gastrointestinal cancer [J].
Bleiberg, H .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) :371-379
[7]   Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer [J].
Boku, N ;
Ohtsu, A ;
Shimada, Y ;
Shirao, K ;
Seki, S ;
Saito, H ;
Sakata, Y ;
Hyodo, I .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :319-323
[8]   Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803 [J].
Bouche, O ;
Raoul, JL ;
Bonnetain, F ;
Giovannini, M ;
Etienne, PL ;
Lledo, G ;
Arsène, D ;
Paitel, JF ;
Guérin-Meyer, V ;
Mitry, E ;
Buecher, B ;
Kaminsky, MC ;
Seitz, JF ;
Rougier, P ;
Bedenne, L ;
Milan, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4319-4328
[9]  
Futatsuki K, 1994, JPN J CANC CHEMOTHER, V21, P1033
[10]   Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer [J].
Glimelius, B ;
Ekstrom, K ;
Hoffman, K ;
Graf, W ;
Sjoden, PO ;
Haglund, U ;
Svensson, C ;
Enander, LK ;
Linne, T ;
Sellstrom, H ;
Heuman, R .
ANNALS OF ONCOLOGY, 1997, 8 (02) :163-168